CGTN
11.6.2020 05:37:05 CEST | Business Wire | Press release
China’s centralized and efficient command system formed a strong guarantee for the country to win the all-out people's war against COVID-19, according to a recently-released government white paper.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200610005922/en/
The document released on June 7 chronicled China's battle against COVID-19, detailing its painstaking yet effective efforts to control the outbreak domestically and its swift responses to contain the spread globally.
The coronavirus caught China unaware, the white paper noted, but the Chinese government acted swiftly to fight the virus and provide medical treatment for patients, prioritizing people's lives and health.
Since the first cases were detected in late December 2019, China has adopted thorough, rigorous and comprehensive prevention and control measures, as well as enforced quarantine and isolation, on a scale never seen before.
Medical resources have been mobilized across the country, and all those in need have been tested, quarantined, hospitalized or treated. With these measures in place, the country was able to contain the outbreak quickly and prevent a wider spread.
The white paper divides China's fight against the epidemic into five stages – "swift response" (December 27, 2019 to January 19, 2020), "initial containment" (January 20 to February 20), "single-digit increase in new domestic cases" (February 21 to March 17), "initial victory in a critical battle" (March 18 to April 28) and "epidemic control, new normal" (from April 29 onwards).
Timeline: China's fight against COVID-19 in five stages
Graphics: Inside China's all-out effort to contain the coronavirus
It took China more than three months to declare an initial victory in the COVID-19 battle, according to the white paper. This was possible as a result of the country's centralized and highly efficient command system, the white paper concluded.
Under the strong leadership of the CPC Central Committee with Xi Jinping at its core, central authorities exercise overall command while local authorities and all sectors follow the leadership and instructions of the central authorities, perform their respective duties and cooperate with each other.
President Xi assumed full command over the control efforts from the beginning of the outbreak. He chaired 14 meetings of the Standing Committee of the Political Bureau of the CPC Central Committee, four meetings of the Political Bureau, meetings of the Central Commission for Law-based Governance, Central Cyberspace Affairs Commission, Central Commission for Further Reform, and Central Commission for Foreign Affairs, and a meeting with prominent non-CPC figures. At these meetings, he heard briefings about epidemic prevention and control work and made decisions on overall plans for strengthening control efforts and international cooperation.
The president inspected community response and COVID-19 research in Beijing, and visited Wuhan to guide the frontline response. He has also inspected Zhejiang, Shaanxi, Shanxi and Gansu provinces, where he was briefed on progress in coordinating epidemic prevention and control with economic and social development, as well as in poverty alleviation.
Meanwhile, the central government coordinated the epidemic control work. Premier Li Keqiang, as head of the Central Leading Group for Novel Coronavirus Prevention and Control, chaired more than 30 meetings regarding COVID-19 control and economic resumption.
On January 7, Xi issued instructions on epidemic prevention and control work when he chaired a meeting of the Standing Committee of the Political Bureau of the CPC Central Committee.
On January 23, Wuhan, a megacity with a population of more than 10 million, was locked down in an unprecedented effort to contain the spread of the virus.
The central government mobilized medical experts and supplies as well as provisions for daily living needs such as food and energy to assist Wuhan and Hubei, and major public health emergency responses were activated across the country.
On January 25, the Standing Committee of the Political Bureau of the CPC Central Committee set up a central leading group on the epidemic, dispatched a central guiding team and demanded a State Council inter-agency task force play a full role in coordination.
The central leading group went to Wuhan to inspect and direct prevention and control of COVID-19 on January 27. Premier Li, who headed the leading group, also went to Wuhan to inspect the front lines.
In meetings with the CPC's senior leaders in early February, Xi called for measures to implement higher admission and treatment rates and lower infection and fatality rates. He also asked governments at all levels to implement targeted policies to contain the outbreak quickly.
Official data showed that many provinces started to lower their major public health emergency response levels from February 21, indicating the COVID-19 outbreak was coming under control.
On March 11, daily new domestic cases fell to single digits for the first time on the Chinese mainland. A week later, the mainland reported no increase in domestic cases for the first time.
As China declared an early victory in the containment of COVID-19 and normalized epidemic prevention and control, the CPC's top leadership made arrangements to steadily lift the travel restrictions and open up economic activity.
On May 7, the central government issued guidelines on normalized epidemic prevention and control.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005922/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group appoints Paolo Paoletti to its Board of Directors29.10.2026 11:01:00 CET | Press release
HIGHLIGHTS:Paolo Paoletti, M.D., joins Chiesi's Board of Directors as its fourth independent member, effective as of today.An internationally recognized pharmaceutical leader, he brings more than 30 years of experience spanning R&D, biotechnology innovation and global healthcare leadership.His appointment further strengthens the Board's scientific and strategic expertise as Chiesi advances its commitment to delivering innovative solutions for patients. Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an internationally recognized pharmaceutical executive with more than 30 years of experience across research and development, corporate leadership and biotechnology innovation. Throughout his career, he has held senior leadership positions at Lilly, GlaxoSmithKline (GSK) and GammaDelta Therapeutics, contributing to the development and commercialization of
Icon Solutions Appoints Raquel Guillot as Southern Europe Sales Director to Drive Global Adoption of the Icon Payments Framework29.10.2026 10:30:00 CET | Press release
Madrid-based appointment will focus on expanding the company’s presence across Southern Europe and developing opportunities in new markets Icon Solutions – the UK fintech enabling banks globally to design and implement state-of-the-art payment systems – has appointed Raquel Guillot as Southern Europe Sales Director, to drive adoption of the Icon Payments Framework (IPF) across the region. Guillot brings around 20 years of experience spanning banking, analytics, fraud prevention, payments and core banking technology. She began her career at Citibank before moving into financial technology, holding roles at SAS, ACI Worldwide and other technology providers, including Thought Machine. IPF is the internationally proven payments development framework trusted by banks across the globe, including Citi, UBS, NatWest and BNP Paribas. It enables banks to transform their systems in an accelerated, structured and low-risk way, all on their own terms. Based in Madrid, Guillot will focus on expandin
Alushibe Holding Group to Bring 12 Global F&B Brands to Libya by 202829.10.2026 09:00:00 CET | Press release
Ahmed Gadalla signs exclusive master franchise agreement with Türkiye's MADO: US$7 million, 7 cafés and 350 jobs in the first phase; 1,000 sq m Benghazi flagship opens Q1 2027 Alushibe Holding Group today announced plans to bring 12 international food-and-beverage brands to Libya by 2028 through its Retail & Destinations division, beginning with an exclusive master franchise agreement with MADO, the Turkish ice-cream and patisserie house founded in 1850. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029822317/en/ Ahmed Gadalla signs exclusive master franchise agreement with Türkiye's MADO: US$7 million, 7 cafés and 350 jobs in the first phase; 1,000 sq m Benghazi flagship opens Q1 2027 – (Photo: AETOSWire) Signed in Kahramanmaraş on 13 October 2026 by Ahmed Gadalla, Founder and Chairman of Alushibe Holding Group, and Mehmet Sait Kanbur, Chairman of MADO, the agreement grants Alushibe exclusive rights to develop and opera
U.S. Bancorp Announces New U.S. Bancorp Global Funds Brand29.10.2026 09:00:00 CET | Press release
The platform also introduces its first offshore liquidity fund, domiciled in Ireland U.S. Bancorp today announced its new fund platform, U.S. Bancorp Global Funds, and its first offering, an offshore liquidity fund domiciled in Ireland, the U.S. Bancorp Liquidity – USD Treasury CNAV Fund. U.S. Bancorp Global Funds was created to support U.S. Bancorp’s growing international presence. It establishes a framework for future investment offerings and reflects U.S. Bancorp’s expanding presence in global markets. Investment products offered under the brand are established through U.S. Bancorp Global Funds ICAV, an Ireland-domiciled UCITS umbrella fund structure. The U.S. Bancorp Liquidity – USD Treasury CNAV Fund is the first offering introduced under the new brand. The U.S. Bancorp Liquidity – USD Treasury CNAV Fund is designed for investors outside the United States seeking to preserve capital while accessing a U.S. Treasury-focused liquidity solution within a regulated offshore structure. D
Element Biosciences Launches AVITI Dx™, Bringing CE-Marked IVD Sequencing to Ten EU Countries29.10.2026 09:00:00 CET | Press release
Integrated sequencing, reagents, and software bring IVDR-compliant sequencing capabilities to European clinical laboratories, with additional global markets planned to follow Element Biosciences, Inc. today announced the commercial launch of AVITI Dx, the company's first CE-marked in vitro diagnostic (IVD) sequencing platform under the European Union's In Vitro Diagnostic Regulation (EU IVDR). AVITI Dx integrates Element’s AVITI™ sequencing system, dedicated reagents, and software designed to meet applicable IVDR requirements and support regulated clinical laboratory workflows. The system is launching commercially in ten EU countries: the Netherlands, Germany, France, Italy, Spain, Austria, the Czech Republic, Latvia, Romania, and Poland, with additional markets planned through a phased approach. Developed and manufactured under Element's ISO 13485-certified quality management system, AVITI Dx is a Class A IVD sequencing system supported by IVDR-compliant reagents and software. Built o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
